Principles and Overview of Allogeneic Hematopoietic Stem Cell Transplantation

  • Sergio Giralt
  • Michael R. Bishop
Part of the Cancer Treatment and Research book series (CTAR, volume 144)

Introduction and Historical Perspectives

Hematopoietic stem cell transplantation (HSCT) is the process and intravenous infusion of hematopoietic stem and progenitor cells to restore normal hematopoiesis and/or treat malignancy [1, 2]. The term “hematopoietic stem cell transplantation” has replaced the term “bone marrow transplantation” (BMT) because hematopoietic stem cells can be derived from a variety of sources other than the bone marrow, including the peripheral blood and umbilical cord blood [2, 3]. Stem cells used for HSCT are distinguished as being of hematopoietic origin, as there is growing interest in using more primitive stem cells for regenerative therapy due to their plasticity and unique biologic characteristics [4]. Hematopoietic stem cells are further characterized according to their source, that is, from whom they are obtained. Hematopoietic stem cells obtained from the patient him- or herself are referred to as autologous [1, 3]. Hematopoietic stem cells obtained...


Human Leukocyte Antigen Hematopoietic Stem Cell Hematopoietic Stem Cell Transplantation Conditioning Regimen Acute GvHD 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Thomas E, Storb R, Clift RA, et al. Bone-marrow transplantation (two parts). N Engl J Med. 1975;292:832–43, 895–902.PubMedGoogle Scholar
  2. 2.
    Weissman IL. Translating stem and progenitor cell biology to the clinic: barriers and opportunities. Science 2000;287:1442–6.PubMedGoogle Scholar
  3. 3.
    Armitage JO. Bone marrow transplantation. N Engl J Med. 1994;330:827–38.PubMedGoogle Scholar
  4. 4.
    Rafii S, Lyden D. Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration. Nat Med. 2003;9:702–12.PubMedGoogle Scholar
  5. 5.
    Clark ML, Lynch FX. Clinical symptoms of radiation sickness, time to onset and duration of symptoms among Hiroshima survivors in the lethal and median lethal ranges of radiation. Mil Surg. 1952;111:360.PubMedGoogle Scholar
  6. 6.
    Jacobson LO, Marks EK, Robson MJ, et al. Effect of spleen protection on mortality following X-irradiation. J Lab Clin Med. 1949;34:1538–43.Google Scholar
  7. 7.
    Rekers PE, Coulter MP, Warren S. Effects of transplantation of bone marrow into irradiated animals. Arch Surg. 1950;60:635.Google Scholar
  8. 8.
    Lorenz E, Uphoff DE, Reid TR, Shelton E. Modification of irradiation injury in mice and guinea pigs by bone marrow injections. J Natl Cancer Inst. 1951;12:197–201.PubMedGoogle Scholar
  9. 9.
    Barnes DW, Corp MJ, et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956;2:626–7.PubMedGoogle Scholar
  10. 10.
    Dameshek W. Bone marrow transplantation; a present-day challenge. Blood 1957;12:321–3.PubMedGoogle Scholar
  11. 11.
    Groth CG, Brent LB, Calne RY, et al. Historic landmarks in clinical transplantation: conclusions from the consensus conference at the University of California, Los Angeles. World J Surg. 2000;24:834–43.PubMedGoogle Scholar
  12. 12.
    Van Rood JJ, Eernisse JG, et al. Leucocyte antibodies in sera from pregnant women. Nature 1958;181:1735–6.Google Scholar
  13. 13.
    Wilson RE, Henry L, Merrill JP. A model system for determining histocompatibility in man. J Clin Invest. 1963;42:1497–503.PubMedGoogle Scholar
  14. 14.
    Dausset J, Rapaport FT, et al. A leucocyte group and its relationship to tissue histocompatibility in man. Transplantation 1965;3:701–5.PubMedGoogle Scholar
  15. 15.
    Mathé G, Amiel JL, Schwartzenberg L, et al. Successful allogeneic bone marrow transplantation in man: chimerism, induced specific tolerance and possible antileukemic effects. Blood 1965:25:179–96.PubMedGoogle Scholar
  16. 16.
    Bach FH, Albertini RJ, et al. Bone-marrow transplantation in a patient with the Wiskott–Aldrich syndrome. Lancet 1968;2:1364–6.PubMedGoogle Scholar
  17. 17.
    Gatti RA, Meuwissen HJ, et al. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968;2:1366–9.PubMedGoogle Scholar
  18. 18.
    De Koning J, Van Bekkum DW et al. Transplantation of bone-marrow cells and fetal thymus in an infant with lymphopenic immunological deficiency. Lancet 1969;1:1223–7.PubMedGoogle Scholar
  19. 19.
    Thomas ED, Buckner CD, et al. Aplastic anemia treated by marrow transplantation. Lancet 1972;i:284–9.Google Scholar
  20. 20.
    Thomas ED, Buckner CD, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977;49:511–33.PubMedGoogle Scholar
  21. 21.
    Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med. 2006;354:1813–26.PubMedGoogle Scholar
  22. 22.
    Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300:1068–73.PubMedGoogle Scholar
  23. 23.
    Weiden PL, Sullivan KM, Flournoy N, et al. Anti-leukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529–33.PubMedGoogle Scholar
  24. 24.
    Butturini A, Bortin MM, et al. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplant. 1987;2:233–42.PubMedGoogle Scholar
  25. 25.
    Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75:555–62.PubMedGoogle Scholar
  26. 26.
    Kolb HJ, Mittermüller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–5.PubMedGoogle Scholar
  27. 27.
    Porter DL, Roth MS, McGarigle C, et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med. 1994;330:100–6.PubMedGoogle Scholar
  28. 28.
    Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995;86:2041–50.PubMedGoogle Scholar
  29. 29.
    Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–44.PubMedGoogle Scholar
  30. 30.
    McCluskey J, Peh CA. The human leucocyte antigens and clinical medicine: an overview. Rev Immunogenet. 1999;1:3–20.PubMedGoogle Scholar
  31. 31.
    Hurley CK, Wade JA, Oudshoorn M, et al. A special report: histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors. Tissue Antigens. 1999;53:394–406.PubMedGoogle Scholar
  32. 32.
    Flomenberg N, Baxter-Lowe LA, Confer D, et al. Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. Blood 2004;104:1923–30.PubMedGoogle Scholar
  33. 33.
    Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med. 1985;313:765–71.PubMedGoogle Scholar
  34. 34.
    Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med. 1993;328:593–602.PubMedGoogle Scholar
  35. 35.
    Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339:1565–77.PubMedGoogle Scholar
  36. 36.
    Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998;339:1186–93.PubMedGoogle Scholar
  37. 37.
    Yakoub-Agha I, Mesnil F, Kuentz M, et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol. 2006;24:5695–702.PubMedGoogle Scholar
  38. 38.
    Grewal SS, Barker JN, Davies SM, Wagner JE. Unrelated donor hematopoietic cell transplantation: marrow or umbilical cord blood? Blood 2003;101:4233–44.PubMedGoogle Scholar
  39. 39.
    Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351:2265–75.PubMedGoogle Scholar
  40. 40.
    Barker JN, Weisdorf DJ, Wagner JE. Creation of a double chimera after the transplantation of umbilical-cord blood from two partially matched unrelated donors. N Engl J Med. 2001;344:1870–1.PubMedGoogle Scholar
  41. 41.
    Fernandez MN, Regidor C, et al. Unrelated umbilical cord blood transplants in adults: early recovery of neutrophils by supportive co-transplantation of a low number of highly purified peripheral blood CD34+ cells from an HLA-haploidentical donor. Exp Hematol. 2003;31:535–44.PubMedGoogle Scholar
  42. 42.
    Henslee-Downey PJ, Abhyankar SH, Parrish RS, et al. Use of partially mismatched related donors extends access to allogeneic marrow transplant. Blood 1997;89:3864–72.PubMedGoogle Scholar
  43. 43.
    O‘Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8:377–86.PubMedGoogle Scholar
  44. 44.
    Buckner CD, Clift RA, Sanders JE, et al. Marrow harvesting from normal donors. Blood 1984;64:630–4.PubMedGoogle Scholar
  45. 45.
    Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringdén O, Barrett AJ; GVHD Working Committee of Center for International Blood and Marrow Transplant Research. ABO blood group barrier in allogeneic bone marrow transplantation revisited. Biol Blood Marrow Transplant. 2005;11:1006–13.PubMedGoogle Scholar
  46. 46.
    Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A; Joint Accreditation Committee, International Society for Cellular Therapy; European Group for Blood and Marrow Transplantation. EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant. 2006;37:1069–85.PubMedGoogle Scholar
  47. 47.
    Stem Cell Trialists‘ Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074–87.Google Scholar
  48. 48.
    Rowley SD, Feng Z, Chen L, et al. A randomized phase III clinical trial of autologous blood stem cell transplantation comparing cryopreservation using dimethylsulfoxide vs dimethylsulfoxide with hydroxyethylstarch. Bone Marrow Transplant. 2003;31:1043–51.PubMedGoogle Scholar
  49. 49.
    Simpson D. T-cell depleting antibodies: new hope for induction of allograft tolerance in bone marrow transplantation? BioDrugs 2003;17:147–54.PubMedGoogle Scholar
  50. 50.
    Baranov A, Gale RP, Guskova A, et al. Bone marrow transplantation after the Chernobyl nuclear accident. N Engl J Med. 1989;321:205–12.PubMedGoogle Scholar
  51. 51.
    Niederwieser D, Maris M, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003;101:1620–9.PubMedGoogle Scholar
  52. 52.
    Santos GW, Sensenbrenner LL, et al. HL-A-identical marrow transplants in aplastic anemia, acute leukemia, and lymphosarcoma employing cyclophosphamide. Transplant Proc. 1976;8:607–10.Google Scholar
  53. 53.
    Tutschka PJ, Copelan EA, et al. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987;70:1382–8.PubMedGoogle Scholar
  54. 54.
    Andersson BS, Kashyap A, et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: A phase II study. Biol Blood Marrow Transplant. 2002;8:145–54.PubMedGoogle Scholar
  55. 55.
    Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531–6.PubMedGoogle Scholar
  56. 56.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756–63.PubMedGoogle Scholar
  57. 57.
    Antin JH. Clinical practice. Long-term care after hematopoietic-cell transplantation in adults. N Engl J Med. 2002;347:36–42.PubMedGoogle Scholar
  58. 58.
    Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106:2912–9.PubMedGoogle Scholar
  59. 59.
    Champlin RE, Horowitz MM, van Bekkum DW, et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989;73:606–13.PubMedGoogle Scholar
  60. 60.
    Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326:845–51.PubMedGoogle Scholar
  61. 61.
    Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.PubMedGoogle Scholar
  62. 62.
    Sullivan KM, Dykewicz CA, Longworth DL, Boeckh M, Baden LR, Rubin RH, Sepkowitz KA; Centers for Disease Control and Prevention; Infectious Diseases Society of America; American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program. 2001: 392–421.Google Scholar
  63. 63.
    Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol. 1995;15:473–9.PubMedGoogle Scholar
  64. 64.
    Ruutu T, Barosi G, Benjamin RJ, Clark RE, George JN, Gratwohl A, Holler E, Iacobelli M, Kentouche K, Lämmle B, Moake JL, Richardson P, Socié G, Zeigler Z, Niederwieser D, Barbui T; European Group for Blood and Marrow Transplantation; European LeukemiaNet. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007;92:95–100.PubMedGoogle Scholar
  65. 65.
    Srinivasan R, Balow JE, Sabnis S, et al. Nephrotic syndrome: an under-recognised immune-mediated complication of non-myeloablative allogeneic haematopoietic cell transplantation. Br J Haematol. 2005;131:74–9.PubMedGoogle Scholar
  66. 66.
    Bearman SI, Anderson GL, Mori M, et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol. 1993;11:1729–36.PubMedGoogle Scholar
  67. 67.
    DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis. 2002;22:27–42.PubMedGoogle Scholar
  68. 68.
    Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh J, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337–43.PubMedGoogle Scholar
  69. 69.
    Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Snyder M, Lewis SK, Allerton JP, Thompson JM. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1998;128(12 Pt 1):975–81.PubMedGoogle Scholar
  70. 70.
    Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–8.PubMedGoogle Scholar
  71. 71.
    Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990;76:1464–72.PubMedGoogle Scholar
  72. 72.
    Kennedy MS, Deeg HJ, Storb R, et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids and cyclosporine. Am J Med. 1985;78:978–83.PubMedGoogle Scholar
  73. 73.
    Jacobsohn DA, Vogelsang GB. Novel pharmacotherapeutic approaches to prevention and treatment of GVHD. Drugs 2002;62:879–89.PubMedGoogle Scholar
  74. 74.
    Shulman HM, Kleiner D, Lee SJ, Morton T, Pavletic SZ, Farmer E, Moresi JM, Greenson J, Janin A, Martin PJ, McDonald G, Flowers ME, Turner M, Atkinson J, Lefkowitch J, Washington MK, Prieto VG, Kim SK, Argenyi Z, Diwan AH, Rashid A, Hiatt K, Couriel D, Schultz K, Hymes S, Vogelsang GB. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group Report. Biol Blood Marrow Transplant. 2006;12:31–47.PubMedGoogle Scholar
  75. 75.
    Lee SJ, Vogelsang G, Flowers ME. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9:215–33.PubMedGoogle Scholar
  76. 76.
    Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11:945–56.PubMedGoogle Scholar
  77. 77.
    Vogelsang GB. How I treat chronic graft-versus-host disease. Blood 2001;97:1196–201.PubMedGoogle Scholar
  78. 78.
    Couriel D, Carpenter PA, Cutler C, Bolaños-Meade J, Treister NS, Gea-Banacloche J, Shaughnessy P, Hymes S, Kim S, Wayne AS, Chien JW, Neumann J, Mitchell S, Syrjala K, Moravec CK, Abramovitz L, Liebermann J, Berger A, Gerber L, Schubert M, Filipovich AH, Weisdorf D, Schubert MM, Shulman H, Schultz K, Mittelman B, Pavletic S, Vogelsang GB, Martin PJ, Lee SJ, Flowers ME. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006;12:375–96.PubMedGoogle Scholar
  79. 79.
    Zittoun RA, Mandelli F, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell‘Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med. 1995;332:217–23.PubMedGoogle Scholar
  80. 80.
    Cassileth PA, Harrington DP, et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med. 1998;339:1649–56.PubMedGoogle Scholar
  81. 81.
    Woods WG, Neudorf S, Gold S, et al. Children‘s Cancer Group: a comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001;97:56–62.PubMedGoogle Scholar
  82. 82.
    Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute myelogenous leukemia in 1st remission. Leuk Res. 1999;23:709–18.PubMedGoogle Scholar
  83. 83.
    Aoudjhane M, Labopin M, Gorin NC, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19:2304–12.PubMedGoogle Scholar
  84. 84.
    Gale RP, Park RE, Dubois RW, Herzig GP, Hocking WG, Horowitz MM, Keating A, Kempin S, Linker CA, Schiffer CA, Wiernik PH, Weisdorf DJ, Rai KR. Delphi-panel analysis of appropriateness of high-dose therapy and bone marrow transplants in adults with acute lymphoblastic leukemia in first remission. Leuk Res. 1998;22:973–81.PubMedGoogle Scholar
  85. 85.
    Thomas X, Boiron JM, Huguet F, Dombret H, Bradstock K, Vey N, Kovacsovics T, Delannoy A, Fegueux N, Fenaux P, Stamatoullas A, Vernant JP, Tournilhac O, Buzyn A, Reman O, Charrin C, Boucheix C, Gabert J, Lhéritier V, Fiere D. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075–86.PubMedGoogle Scholar
  86. 86.
    Hunault M, Harousseau JL, Delain M, Truchan-Graczyk M, Cahn JY, Witz F, Lamy T, Pignon B, Jouet JP, Garidi R, Caillot D, Berthou C, Guyotat D, Sadoun A, Sotto JJ, Lioure B, Casassus P, Solal-Celigny P, Stalnikiewicz L, Audhuy B, Blanchet O, Baranger L, Béné MC, Ifrah N; GOELAMS (Groupe Ouest-Est des Leucémies Airguës et Maladies du Sang) Group. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood 2004;104:3028–37.PubMedGoogle Scholar
  87. 87.
    Fielding AK, Richards SM, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007;109:944–50.PubMedGoogle Scholar
  88. 88.
    Radich JP, Gooley T, et al. HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. Blood 2003;102:31–5.PubMedGoogle Scholar
  89. 89.
    Giralt SA, Arora M, et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol. 2007;137:461–7.PubMedGoogle Scholar
  90. 90.
    Crawley C, Iacobelli S, et al. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007;109:3588–94.PubMedGoogle Scholar
  91. 91.
    Weisser M, Schleuning M, et al. Allogeneic stem-cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leuk Lymphoma. 2007;48:295–301.PubMedGoogle Scholar
  92. 92.
    Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002;100:1997–2004.PubMedGoogle Scholar
  93. 93.
    Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low risk myelodysplasia is associated with improved outcome. Blood 2004;104:579–85.PubMedGoogle Scholar
  94. 94.
    Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23:9387–93.PubMedGoogle Scholar
  95. 95.
    Martino R, Iacobelli S, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006;108:836–46.PubMedGoogle Scholar
  96. 96.
    Ratanatharathorn V, Uberti J, Karanes C, et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin‘s lymphoma. Blood 1994;84:1050–5.PubMedGoogle Scholar
  97. 97.
    Bierman PJ, Sweetenham JW, Loberiza FR Jr, et al. Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin‘s lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2003;21:3744–53.PubMedGoogle Scholar
  98. 98.
    Robinson SP, Goldstone AH, Mackinnon S, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002;100:4310–6.PubMedGoogle Scholar
  99. 99.
    Grigg A, Ritchie D. Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004;10:579–90.PubMedGoogle Scholar
  100. 100.
    Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin‘s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 2005;365:1934–41.PubMedGoogle Scholar
  101. 101.
    Barlogie B, Kyle RA, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24:929–36.PubMedGoogle Scholar
  102. 102.
    Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356:1110–20.PubMedGoogle Scholar
  103. 103.
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–8.PubMedGoogle Scholar
  104. 104.
    Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22:3886–92.PubMedGoogle Scholar
  105. 105.
    Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005;366:318–320.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations